FDA approves Alpha Cognition’s ZUNVEYL for Alzheimer’s treatment
Formerly known as ALPHA-1062, the therapy is said to have a dual mechanism of action aimed at improving tolerability and maintaining the efficacy of galantamine, its active moiety.
Health Canada has granted approval for Celltrion Healthcare Canada’s Steqeyma (ustekinumab injection) and Steqeyma IV (ustekinumab for injection, solution for intravenous infusion) for treating various chronic inflammatory conditions.
Ackermans & van Haaren spearheaded the investment round, with participation from both new investors including Driehaus Capital Management and Quest for Growth. Current investors namely BioGeneration Ventures, Capricorn
This alliance is aimed at transforming scientific breakthroughs at Oxford into potential new treatments. Under the deal, Apollo will detect and evaluate established therapeutic targets from Oxford’s biomedical